Illustrative image.
Tukysa
Tucatinib
$7000.00
50mg · 2 × 88 tablets · 3 months supply
BrandBranded medicine· By Pfizer
$2333.33 per month
Strength
How long a supply?
Test mode: no payment is taken. View cart
Annual cost
$28000a year at this pack size
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
50mg
150mg
About Tukysa
Overview
Tukysa (tucatinib) is a kinase inhibitor used with trastuzumab and capecitabine for adults with HER2-positive breast cancer that cannot be removed by surgery or has spread, including to the brain, after at least one previous anti-HER2 treatment for metastatic disease. It is also used with trastuzumab for adults with RAS wild-type, HER2-positive colorectal cancer that cannot be removed by surgery or has spread and has progressed after fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. The colorectal cancer use has accelerated FDA approval based on tumor response and how long responses lasted; continued approval may depend on confirmatory trials verifying clinical benefit. Tucatinib blocks HER2 signals involved in cancer cell growth.
What it treats
- Advanced HER2-positive breast cancer that cannot be removed by surgery or has spread, including to the brain, in adults who have received at least one prior anti-HER2 treatment regimen for metastatic disease. Used with trastuzumab and capecitabine. - RAS wild-type, HER2-positive colorectal cancer that cannot be removed by surgery or has spread, in adults whose cancer has progressed after fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. Used with trastuzumab. This indication has accelerated approval based on tumour response rate and duration of response; continued approval may depend on confirmatory trials verifying clinical benefit.
Safety information
Side effects
Common side effects depend on the medicines used with Tukysa. With trastuzumab and capecitabine for metastatic breast cancer, they include diarrhea, redness and soreness of the palms and soles (hand-foot syndrome), nausea, liver toxicity, vomiting, inflammation or sores in the mouth, decreased appetite, anemia and rash. With trastuzumab for colorectal cancer that cannot be removed by surgery or has spread, they include diarrhea, fatigue, rash, nausea, abdominal pain, infusion-related reactions and fever. Contact your doctor promptly if you develop severe diarrhea. It can lead to dehydration, sudden kidney injury and death. Severe liver toxicity has also been reported. Your doctor will check liver blood tests before treatment, every three weeks during treatment and as needed. Depending on the severity of diarrhea or liver toxicity, treatment may need to be interrupted, reduced or stopped by your doctor. Tukysa can harm an unborn baby. Use effective contraception and contact your doctor if you become pregnant during treatment. Pregnancy and contraception precautions also apply to trastuzumab and capecitabine when used with Tukysa.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
The label lists no contraindications for Tukysa. Important warnings and precautions include: • Severe diarrhea, which can lead to dehydration, acute kidney injury and death. Depending on severity, treatment may need to be interrupted, reduced or stopped permanently. • Severe liver damage. Liver blood tests (ALT, AST and bilirubin) are required before treatment, every 3 weeks during treatment and as clinically indicated. Treatment changes may be needed if liver problems occur. • Harm to an unborn baby. Use effective contraception during treatment. Consult the prescribing information for trastuzumab and capecitabine for their pregnancy and contraception advice. • Breastfeeding is not advised.
Interactions
Tukysa can interact with medicines processed by certain enzymes or transport proteins. Tell your doctor if you take: • Strong CYP3A inducers or moderate CYP2C8 inducers: use with Tukysa should be avoided. • Strong CYP2C8 inhibitors: use together should be avoided. If unavoidable, your doctor will need to adjust your Tukysa treatment. • CYP3A substrates: use together should be avoided when even small increases in their levels could cause serious or life-threatening side effects. • P-gp substrates: your doctor may need to adjust these medicines when small increases in their levels could cause serious or life-threatening side effects. Your doctor or pharmacist can check whether your medicines belong to these groups.
Using Tukysa
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store below 25°C in a dry place, in the original pack, away from direct light and moisture. Do not keep it in a bathroom. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label TUKYSA (TUCATINIB) TABLET [SEAGEN INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00